quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:13:01·55d
ANALYSTRating
Polaryx Therapeutics Inc. logo

Maxim Group initiated coverage on Polaryx Therapeutics with a new price target

PLYX· Polaryx Therapeutics Inc.
Health Care
Original source

Companies

  • PLYX
    Polaryx Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Feb 27UpdateMaxim Group$10.00

Related

  • PR22h
    Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
  • PR2d
    Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
  • PR8d
    Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
  • PR22d
    Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
  • PR37d
    Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
  • PR42d
    Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
  • PR55d
    Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
  • INSIDER62d
    Chief Financial Officer Landis G. Michael bought $7,991 worth of shares (2,867 units at $2.79), increasing direct ownership by 1% to 228,225 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022